Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller showdown: can a Long-Acting drug beat standard care for surgery pain?

NCT ID NCT07271979

Symptom relief Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests if a long-acting painkiller (liposomal bupivacaine) works better than a standard one (ropivacaine) for pain after upper abdominal surgery. About 146 adults having open surgery will receive one of the two drugs injected into the belly lining before the incision is closed. The main goal is to see which drug reduces pain scores and the need for extra pain medicine in the first 24 hours.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

146 people

The number who actually took part.

Started

Jan 2026

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 to 75 years; for those \>70 years old, a Karnofsky Performance Status (KPS) score ≥80 is required. 2. Scheduled for elective upper abdominal laparotomy. 3. Surgical approach involving either a subcostal or midline incision. 4. Incision length between 15 and 30 cm. 5. American Society of Anesthesiologists (ASA) physical status classification of I to III. Exclusion Criteria: 1. ASA Physical Status Class greater than III. 2. Pre-existing chronic pain with long-term opioid use (for \>1 year). 3. Significant hepatic or renal impairment, or underweight status, defined as: Estimated glomerular filtration rate (eGFR) of \<40 mL/min/1.73m²; Child-Pugh Class C; Body Mass Index (BMI) \<18.5 kg/m². 4. Known allergy or hypersensitivity to the investigational drug or any of its excipients. 5. Pregnancy or lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Analgesia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia pain agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Analgesia Liposomal bupivacaine Preperitoneal infiltration

Contacts and locations

Locations

  • Qilu Hospital of Shandong University

    Jinan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.